我国利福平耐药结核病防治的历史沿革及展望  

Historical evolution and prospect of rifampicin-resistant tuberculosis prevention and control in China

作　　者：阮云洲[1] 苏伟[1] 张慧[1] 赵雁林[1] Ruan Yunzhou;Su Wei;Zhang Hui;Zhao Yanlin(National Center for Tuberculosis Control and Prevention,Chinese Center for Disease Control and Prevention/National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases,Beijing 102206,China)

机构地区：[1]中国疾病预防控制中心结核病预防控制中心/传染病溯源预警与智能决策全国重点实验室

出　　处：《中国防痨杂志》2024年第10期1166-1170,共5页Chinese Journal of Antituberculosis

基　　金：结核病预防控制项目(2428)。

摘　　要：利福平耐药结核病(rifampicin resistant tuberculosis,RR-TB)是我国面临的重大公共卫生问题。如何防治耐药结核病,降低其对社会和民众的危害,笔者从探索研究、规划实施和全面推广3个阶段出发,全面回顾了我国耐药结核病防治的历史沿革,从一无所有的探索,到创新性地建立耐药结核病防治新模式,以及所取得的成效。与此同时,针对当前我国复治结核病患者耐药率高、治疗成功率不理想等挑战,作者也提出了下一步的应对建议和展望,以供读者参考。Rifampicin-resistant tuberculosis(RR-TB)is a major public health problem facing in China.How to control and prevent drug-resistant tuberculosis and reduce its harm to society and the public,the author comprehensively reviewed the historical evolution of drug-resistant tuberculosis control and prevention in China from three stages:exploration and research,planning and implementation,and comprehensive promotion.From the exploration of nothing,to the innovative establishment of a new model for drug-resistant tuberculosis control and prevention and the results achieved.At the same time,in response to the challenges of high rifampicin-resistance rate with retreated patients and unsatisfactory treatment success rate of among patients undergoing treatment in China,the author also puts forward suggestions and prospects for the next steps for your reference.

关 键 词：抗药性 结核 利福平 综合预防 治疗学 

分 类 号：R52[医药卫生—内科学]